FBT 📈 First Trust NYSE Arca - Overview
Exchange: NYSE ARCA • Country: USA • Currency: USD • Type: Etf • ISIN: US33733E2037 • Health
FBT: Biotechnology, Pharmaceuticals, Medical, Research, Genomics, Diagnostics
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the securities that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of 30 leading biotechnology companies. ‣ Company URL: http://www.ftportfolios.com/ ‣ Domicile: United States
Additional Sources for FBT ETF
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
FBT ETF Overview
| Market Cap in USD | 1,188m |
| Category | Health |
| TER | 0.56% |
| IPO / Inception | 2006-06-19 |
FBT ETF Ratings
| Growth 5y | 14.6% |
| Fundamental | - |
| Dividend | 1.0% |
| Rel. Strength Industry | -64.8 |
| Analysts | - |
| Fair Price Momentum | 152.38 USD |
| Fair Price DCF | - |
FBT Dividends
| Dividend Yield 12m | 0.00% |
| Yield on Cost 5y | % |
| Annual Growth 5y | -100.00% |
| Payout Consistency | 6.3% |
FBT Growth Ratios
| Growth Correlation 3m | 11.1% |
| Growth Correlation 12m | 78.1% |
| Growth Correlation 5y | -4.3% |
| CAGR 5y | 1.86% |
| CAGR/Mean DD 5y | 0.14 |
| Sharpe Ratio 12m | 0.15 |
| Alpha | -15.86 |
| Beta | 0.80 |
| Volatility | 25.82% |
| Current Volume | 21.9k |
| Average Volume 20d | 21.1k |
What is the price of FBT stocks?
As of December 22, 2024, the stock is trading at USD 165.53 with a total of 21,900 shares traded.
Over the past week, the price has changed by -2.41%, over one month by +0.36%, over three months by -3.66% and over the past year by +9.65%.
As of December 22, 2024, the stock is trading at USD 165.53 with a total of 21,900 shares traded.
Over the past week, the price has changed by -2.41%, over one month by +0.36%, over three months by -3.66% and over the past year by +9.65%.
Is First Trust NYSE Arca a good stock to buy?
Neither. Based on ValueRay Analyses, First Trust NYSE Arca is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of 14.59 and therefor a technical neutral rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of FBT as of December 2024 is 152.38. This means that FBT is currently overvalued and has a potential downside of -7.94%.
Neither. Based on ValueRay Analyses, First Trust NYSE Arca is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of 14.59 and therefor a technical neutral rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of FBT as of December 2024 is 152.38. This means that FBT is currently overvalued and has a potential downside of -7.94%.
Is FBT a buy, sell or hold?
First Trust NYSE Arca has no consensus analysts rating.
First Trust NYSE Arca has no consensus analysts rating.
What are the forecast for FBT stock price target?
According to ValueRays Forecast Model, FBT First Trust NYSE Arca will be worth about 168.4 in December 2025. The stock is currently trading at 165.53. This means that the stock has a potential upside of +1.71%.
According to ValueRays Forecast Model, FBT First Trust NYSE Arca will be worth about 168.4 in December 2025. The stock is currently trading at 165.53. This means that the stock has a potential upside of +1.71%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 168.4 | 1.7% |